Skip to main content

NCBiotech News

  • Researchers from Durham-based Aldagen have reported positive early clinical study results for two of the firm's lead products, stem cell therapies designed to improve blood flow to the limbs and hearts of people suffering from circulatory problems. Aldagen is a biopharmaceutical company developing proprietary regenerative cell therapies that target unmet medical needs.
  • Morrisville-based drug development firm Addrenex has converted start-up loan help from the North Carolina Biotechnology Center into a $29 million buy-out. Founded in 2006 with the help of $160,000 in loans from the Biotechnology Center, Addrenex has been purchased by Atlanta-based Sciele Pharma, a subsidiary of Osaka, Japan's Shionogi pharmaceutical company.
  • A woman with extensive credentials in science and medicine returned to the UNC Charlotte campus for two days recently to support the university's efforts to recruit and promote women on its science and math faculty.
  • Eerum Husain, 15, an artistic sophomore at Green Hope High School in Cary, has won $250 and second-place honors in a biotechnology poster competition involving hundreds of students in 10th, 11th and 12th grades throughout the United States and Canada. Husain's biology teacher, Master Teacher Rebecca Townsend, has been involved in numerous educational outreach programs with the North Carolina Biotechnology Center.
  • Students from eight North Carolina universities will be able to study food science and nutrition at the North Carolina Research Campus in Kannapolis, thanks to a $1 million grant from the U.S. Department of Agriculture. The grant will be used to expose graduate students to what is known as a transdisciplinary approach to problem-solving, according to Jack Odle, Ph.D., William Neal Reynolds professor of nutritional biochemistry at North Carolina State University. Odle led the effort to apply for the grant and will direct the program.
  • Pioneer Surgical Technology, which has a research facility in Greenville started with the help of $190,000 in funding from the North Carolina Biotechnology Center in 1995, has entered the Chinese market with its full range of spinal-fusion products. Pioneer's Chinese partner, Bonovo Orthopedics, Inc., a manufacturer and distributor of orthopedic products, has received its government's approval to distribute Pioneer's full product line there.
  • Well in advance of tonight's celebration of biotech's growth in the Piedmont Triad, Becky Dougherty walked into the Marriott Convention Center. Becky and her colleage from Prudential Carolinas Realty, Samantha Woltz, took on the job of sorting through name tags. Once the As and Bs and Cs were all together, they arranged them on a black velvet table awaiting the event's 300 attendees. Many Tasks
  • While the Novartis vaccine plant is only now officially opening, Shannon Manning is already one of its proudest boosters. Manning is a production engineer in the automation engineering department. But it's his path to the job with the pharmaceutical giant that makes him an evangelist. Manning, 32, a native of the Nash County town of Middlesex, developed an interest in science while attending Southern Nash High School. He took advanced placement chemistry, physics, and even became a lab assistant.
  • Salix Pharmaceuticals this week closed a sale of 6.325 million shares of stock to raise $128.2 million for company operations. The shares of common stock sold for $21 a share, and was trading over $23 per share on Wednesday (Nov. 25) afternoon. The company's stock received a boost in September, when it won approval from the FDA for Metozolv as a treatment for gastroparesis. It also announced significant results for Rifaximin as a treatment for Irritable Bowel Syndrome.
  • Emerging North Carolina bioscience companies are encouraged to apply by Friday, Dec. 11, for the chance to present themselves to venture capital funding specialists and other interested people at the 2010 Southeast Venture Conference, to be held February 24 and 25 in suburban Washington, D.C.
  • Wilmington-based contract research organization PPD has completed another in a recent series of major business expansions in China. The firm said it has closed on its $77 million acquisition of BioDuro, a 660-employee CRO that PPD says is China's largest such drug discovery and services firm. PPD also recently bought Excel PharmaStudies, another large Chinese CRO, giving PPD 1,000 employees in China. The company now operates in 38 countries and has more than 10,500 employees.  
  • Winston-Salem-based Targacept has entered a collaboration and license agreement with AstraZeneca that could provide more than $1.2 billion in milestone and royalty payments from a drug borne of an earlier disappointment. The drug, TC-5214 is an experimental augmentation therapy, or "add-on drug," to treat major depressive disorder (MDD). It's chemically similar to an experimental MDD drug previously shelved by Targacept. But TC-5214 appears to be safer and more effective. Under terms of the agreement AstraZeneca agreed to pay Targacept:
  • Bioscience companies throughout North Carolina can get reduced-price Internet access to science and business information, thanks to contract pricing arranged by the information specialists at the North Carolina Biotechnology Center library. The service, especially useful to emerging companies around the state that have limited budgets, includes:
  • How do you get science to thrive in the midst of economic decline? Leaders at the Research Triangle Regional Partnership often answer that question.
  • What economic crisis? Syngenta Biotechnology Inc. is proof you don't need to develop a swell swine flu vaccine or a cancer drug to be a biotech powerhouse. In fact, even as it celebrated 25 years of biotech breakthroughs at its Research Triangle Park research headquarters Friday, SBI is hiring workers, buying land and launching products.
  • North Carolina has a new system for getting drug discoveries into the development pipeline. The North Carolina Biotechnology Center has approved a $2.5 million Phase II grant that will be doled out as milestones are met, to support the next four years of building a statewide Drug Discovery Center of Innovation ((DDCOI).
  • Tranzyme Pharma, a 6-year-old Research Triangle Park firm developing drugs for gastrointestinal and metabolic diseases, has signed a multi-million-dollar partnership agreement with pharmaceutical giant Bristol-Myers Squibb.
  • Cary-based Trana Discovery, which got a boost last year through a $250,000 Small Business Research Loan from the North Carolina Biotechnology Center, has completed a $720,000 Series A round of venture funding. The funding means Trana has so far amassed more than $1.4 million to help the 9-year-old firm commercialize its proprietary technology for quickly identifying new drugs to fight viral and bacterial infections, such as HIV and staph.
  • Duke University is among nine organizations receiving $35 million from the federal Biomedical Advanced Research and Development Authority (BARDA) to help devise better radiation detection systems. The contracts, to corporations and universities across the country, seek more-effective tests and devices to determine the level of radiation a person has absorbed after a nuclear or radiological incident. They total $35 million for this initial phase and up to $400 million over five years.
  • North Carolina-based non-profit organizations can help their communities become biotech business beneficiaries. How? By pursuing up to $75,000 in grant funding from the North Carolina Biotechnology Center's Regional Development Grant program. But a January 27 deadline is fast approaching.

Pages

Subscribe to News & Events